306 related articles for article (PubMed ID: 31605269)
1. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere C; Bassanelli M; Ceribelli A; Rasul S; Li S; Prior JO; Cicone F
Curr Urol Rep; 2019 Oct; 20(11):68. PubMed ID: 31605269
[TBL] [Abstract][Full Text] [Related]
2. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
3. The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Evangelista L; Basso U; Maruzzo M; Novara G
Eur Urol Focus; 2020 Jan; 6(1):146-150. PubMed ID: 30120074
[TBL] [Abstract][Full Text] [Related]
4. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
5. Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease.
Rhee H; Ng KL; Tse BW; Yeh MC; Russell PJ; Nelson C; Thomas P; Samaratunga H; Vela I; Gobe G; Wood S
Pathology; 2016 Oct; 48(6):613-6. PubMed ID: 27567227
[No Abstract] [Full Text] [Related]
6. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
7. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Ahn T; Roberts MJ; Abduljabar A; Joshi A; Perera M; Rhee H; Wood S; Vela I
Mol Imaging Biol; 2019 Oct; 21(5):799-807. PubMed ID: 30617728
[TBL] [Abstract][Full Text] [Related]
8. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted
Meyer AR; Carducci MA; Denmeade SR; Markowski MC; Pomper MG; Pierorazio PM; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2019 Aug; 33(8):617-623. PubMed ID: 31147927
[TBL] [Abstract][Full Text] [Related]
9. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.
Urso L; Castello A; Rocca GC; Lancia F; Panareo S; Cittanti C; Uccelli L; Florimonte L; Castellani M; Ippolito C; Frassoldati A; Bartolomei M
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1299-1311. PubMed ID: 35217902
[TBL] [Abstract][Full Text] [Related]
10. PSMA-Targeted
Gorin MA; Rowe SP; Hooper JE; Kates M; Hammers HJ; Szabo Z; Pomper MG; Allaf ME
Eur Urol; 2017 Jan; 71(1):145-146. PubMed ID: 27363386
[No Abstract] [Full Text] [Related]
11. Diagnostic potential of PET/CT using a
Sawicki LM; Buchbender C; Boos J; Giessing M; Ermert J; Antke C; Antoch G; Hautzel H
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):102-107. PubMed ID: 26996777
[TBL] [Abstract][Full Text] [Related]
12. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
[TBL] [Abstract][Full Text] [Related]
13. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis.
Singhal T; Singh P; Parida GK; Agrawal K
Ann Nucl Med; 2024 Mar; 38(3):176-187. PubMed ID: 38340144
[TBL] [Abstract][Full Text] [Related]
14. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Siva S; Udovicich C; Tran B; Zargar H; Murphy DG; Hofman MS
Nat Rev Urol; 2020 Feb; 17(2):107-118. PubMed ID: 31937920
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
16. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
17. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
[TBL] [Abstract][Full Text] [Related]
18. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
19. 68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.
Einspieler I; Tauber R; Maurer T; Schwaiger M; Eiber M
Clin Nucl Med; 2016 May; 41(5):e261-2. PubMed ID: 26859205
[TBL] [Abstract][Full Text] [Related]
20. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
Baccala A; Sercia L; Li J; Heston W; Zhou M
Urology; 2007 Aug; 70(2):385-90. PubMed ID: 17826525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]